Covered recipient · General Payments record
PATRICIA CLEMENT LEE
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$7,655.63
58 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,517.06 | 46 |
| Travel and Lodging | $2,638.57 | 11 |
| Consulting Fee | $1,500.00 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $3,055.98 | 12 |
| E.R. Squibb & Sons, L.L.C. | $1,500.00 | 1 |
| AbbVie, Inc. | $914.11 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $908.50 | 8 |
| Sun Pharmaceutical Industries Inc. | $567.18 | 11 |
| Celgene Corporation | $249.14 | 2 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $138.54 | 2 |
| Janssen Biotech, Inc. | $135.20 | 3 |
| LEO Pharma Inc. | $91.72 | 1 |
| Almirall LLC | $58.43 | 1 |
| GENZYME CORPORATION | $20.36 | 1 |
| Mayne Pharma Inc. | $16.47 | 1 |
Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PATRICIA CLEMENT LEE
NPI 1831335918 · CMS profile ID 264427
Allopathic & Osteopathic Physicians / Dermatology
WEBSTER, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1831335918?year=2019&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PATRICIA CLEMENT LEE, NPI 1831335918, CMS profile ID 264427. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831335918?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). PATRICIA CLEMENT LEE, NPI 1831335918, CMS profile ID 264427. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831335918?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- PATRICIA CLEMENT LEE, NPI 1831335918, CMS profile ID 264427, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1831335918?year=2019&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
58 matching records · $7,655.63 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–58 of 58.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $346.50 | 02/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700437919 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $65.00 | 01/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700437917 | CMS |
| Janssen Biotech, Inc. | $6.60 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658550655 | CMS |
| PFIZER INC. | $494.94 | 01/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671929901 | CMS |
| PFIZER INC. | $364.19 | 01/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671929903 | CMS |
| PFIZER INC. | $249.47 | 01/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671929905 | CMS |
| PFIZER INC. | $241.50 | 01/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671929907 | CMS |
| Sun Pharmaceutical Industries Inc. | $79.43 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704594761 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,472.48 | 7 |
| PY2025 | Principal investigator | $738,419.17 | 172 |
| PY2024 | Recipient | $7,538.98 | 6 |
| PY2024 | Principal investigator | $758,133.92 | 214 |
| PY2023 | Recipient | $10,166.24 | 5 |
| PY2023 | Principal investigator | $421,943.71 | 247 |
| PY2022 | Recipient | $215.00 | 1 |
| PY2022 | Principal investigator | $734,300.41 | 117 |
| PY2021 | Recipient | $3,287.00 | 2 |
| PY2021 | Principal investigator | $1,158,956.90 | 121 |
| PY2020 | Recipient | $6,033.30 | 4 |
| PY2020 | Principal investigator | $1,446,370.96 | 178 |
| PY2019 | Recipient | $9,724.30 | 2 |
| PY2019 | Principal investigator | $1,922,759.40 | 169 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
179 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $665.04 | 12/31/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202534067 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,520.00 | 12/25/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384787 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,125.00 | 12/24/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430996 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,202.00 | 12/19/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385081 |
| Principal investigator 1 | ABBVIE INC. | $185.90 | 12/18/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202531288 |
| Principal investigator 1 | ABBVIE INC. | $416.00 | 12/18/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202531290 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,514.00 | 12/15/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385102 |
| Principal investigator 1 | ABBVIE INC. | $1,413.12 | 12/11/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202530074 |
| Principal investigator 1 | ABBVIE INC. | $128.00 | 12/11/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202530188 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $506.21 | 12/11/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119555 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $105.74 | 12/11/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119557 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $87.12 | 12/11/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119559 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $30.42 | 12/11/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119561 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $76.06 | 12/11/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119563 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $55.31 | 12/11/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119565 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $945.10 | 12/11/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430986 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $600.00 | 12/11/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430988 |
| Principal investigator 1 | ABBVIE INC. | $4,286.10 | 12/10/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202529882 |
| Principal investigator 1 | ABBVIE INC. | $3,791.20 | 12/10/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202529884 |
| Principal investigator 1 | ABBVIE INC. | $1,134.90 | 12/09/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202529746 |
| Principal investigator 1 | ABBVIE INC. | $3,215.00 | 12/04/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202527600 |
| Principal investigator 1 | ABBVIE INC. | $311.84 | 12/02/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202526282 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $611.62 | 12/02/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119553 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,040.00 | 12/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385090 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,803.00 | 12/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175385186 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $97.50 | 12/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223288995 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,928.90 | 12/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289047 |
| Principal investigator 1 | PFIZER INC. | $1,606.15 | 11/26/2025 | Non-covered Recipient Entity Center for Clinical Studies LTD LLP | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228724788 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7.16 | 11/24/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384697 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7.00 | 11/24/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385219 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21.57 | 11/17/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384869 |
| Principal investigator 1 | Janssen Research & Development, LLC | $260.00 | 11/17/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385174 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 11/17/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385193 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $45.00 | 11/12/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223288287 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,549.55 | 11/11/2025 | Non-covered Recipient Entity Center For Clinical Studies | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | No dispute reported | 06/30/2026 | 1235998234 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,477.05 | 11/10/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190313827 |
| Principal investigator 1 | ABBVIE INC. | $532.00 | 11/04/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202520825 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,366.00 | 10/31/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area | No dispute reported | 06/30/2026 | 1175384970 |
| Principal investigator 1 | PFIZER INC. | $1,902.55 | 10/31/2025 | Non-covered Recipient Entity Center for Clinical Studies LTD LLP | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228742047 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,992.00 | 10/24/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384949 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $297.47 | 10/24/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287649 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $104.23 | 10/24/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287667 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,828.80 | 10/22/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287277 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 10/17/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384749 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $385.00 | 10/15/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286989 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $600.00 | 10/15/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286991 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $638.30 | 10/14/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430978 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,499.00 | 10/14/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430982 |
| Principal investigator 1 | ABBVIE INC. | $1,399.84 | 10/09/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202513811 |
| Principal investigator 1 | ABBVIE INC. | $3,134.90 | 10/09/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202515195 |
| Principal investigator 1 | ABBVIE INC. | $2,117.00 | 10/09/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202515197 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $300.00 | 10/09/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430976 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,830.00 | 10/08/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286573 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 10/08/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286575 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,947.00 | 10/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286067 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,262.00 | 09/29/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384805 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,681.00 | 09/29/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384891 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,920.00 | 09/22/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384923 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $790.00 | 09/22/2025 | Non-covered Recipient Entity Center For Clinical Studies Ltd Llp | A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1226084157 |
| Principal investigator 1 | PFIZER INC. | $4,546.10 | 09/09/2025 | Non-covered Recipient Entity Center for Clinical Studies LTD LLP | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228750894 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,040.00 | 09/08/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385040 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,427.00 | 09/08/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175385065 |
| Principal investigator 1 | ABBVIE INC. | $2,657.10 | 09/04/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202509206 |
| Principal investigator 1 | ABBVIE INC. | $1,293.80 | 09/04/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202509356 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,786.00 | 09/04/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175385232 |
| Principal investigator 1 | ABBVIE INC. | $1,596.00 | 09/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202507811 |
| Principal investigator 1 | ABBVIE INC. | $1,399.84 | 09/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202507813 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,204.20 | 09/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285057 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,920.00 | 09/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384821 |
| Principal investigator 1 | Janssen Research & Development, LLC | $858.00 | 08/29/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175385129 |
| Principal investigator 1 | ABBVIE INC. | $13.52 | 08/28/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202506465 |
| Principal investigator 1 | ABBVIE INC. | $1,160.90 | 08/28/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202506467 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,262.00 | 08/25/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384843 |
| Principal investigator 1 | ABBVIE INC. | $28.74 | 08/22/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202505619 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,254.25 | 08/15/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284331 |
| Principal investigator 1 | ABBVIE INC. | $230.77 | 08/14/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202504631 |
| Principal investigator 1 | ABBVIE INC. | $1,244.40 | 08/06/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202502478 |
| Principal investigator 1 | ABBVIE INC. | $3,300.60 | 08/06/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202503317 |
| Principal investigator 1 | ABBVIE INC. | $3,717.60 | 08/05/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202501290 |
| Principal investigator 1 | ABBVIE INC. | $2,076.60 | 08/05/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202501996 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,427.00 | 08/04/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175385140 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,295.50 | 08/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283565 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $300.00 | 08/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283567 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 08/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283569 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,400.70 | 08/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283703 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,948.40 | 08/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283705 |
| Principal investigator 1 | ABBVIE INC. | $2,579.20 | 07/30/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202500504 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,353.00 | 07/28/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384691 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24.38 | 07/28/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385096 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,715.00 | 07/28/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385198 |
| Principal investigator 1 | ABBVIE INC. | $6.03 | 07/17/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202498524 |
| Principal investigator 1 | ABBVIE INC. | $29.39 | 07/17/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202498528 |
| Principal investigator 1 | ABBVIE INC. | $19.66 | 07/17/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202498598 |
| Principal investigator 1 | ABBVIE INC. | $26.09 | 07/15/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202498240 |
| Principal investigator 1 | ABBVIE INC. | $119.93 | 07/15/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202498276 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 07/15/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202498278 |
| Principal investigator 1 | Janssen Research & Development, LLC | $125.00 | 07/14/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384733 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7.29 | 07/14/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384794 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5.14 | 07/14/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175385070 |
| Principal investigator 1 | ABBVIE INC. | $72.49 | 07/10/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202497972 |
| Principal investigator 1 | ABBVIE INC. | $5,880.50 | 07/09/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497564 |
| Principal investigator 1 | ABBVIE INC. | $3,321.00 | 07/09/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497642 |
| Principal investigator 1 | ABBVIE INC. | $4,235.30 | 07/08/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202497200 |
| Principal investigator 1 | ABBVIE INC. | $2,538.20 | 07/08/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497206 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18.34 | 07/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384982 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11.82 | 07/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175385124 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,243.00 | 07/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385169 |
| Principal investigator 1 | ABBVIE INC. | $355.66 | 07/02/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202495043 |
| Principal investigator 1 | ABBVIE INC. | $1,239.20 | 07/02/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202495061 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $550.00 | 07/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LT | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223282022 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,248.00 | 06/30/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385017 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,913.00 | 06/27/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384686 |
| Principal investigator 1 | PFIZER INC. | $12,435.00 | 06/26/2025 | Non-covered Recipient Entity Center for Clinical Studies LTD LLP | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228793353 |
| Principal investigator 1 | ABBVIE INC. | $178.81 | 06/24/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202492755 |
| Principal investigator 1 | ABBVIE INC. | $1,290.90 | 06/18/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202492045 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 06/18/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223281592 |
| Principal investigator 1 | ABBVIE INC. | $20.30 | 06/17/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202491685 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $24,986.00 | 06/13/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223281258 |
| Principal investigator 1 | ABBVIE INC. | $355.66 | 06/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202487391 |
| Principal investigator 1 | ABBVIE INC. | $2,487.20 | 06/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202487565 |
| Principal investigator 1 | ABBVIE INC. | $532.00 | 06/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202487567 |
| Principal investigator 1 | Janssen Research & Development, LLC | $230.00 | 05/30/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385046 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,911.45 | 05/28/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280478 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,913.00 | 05/26/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385034 |
| Principal investigator 1 | Eli Lilly and Company | $20,802.00 | 05/23/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187879291 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,739.00 | 05/22/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175384753 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28.41 | 05/16/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175385023 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,990.00 | 05/09/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175384759 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,720.00 | 05/09/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175385004 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,549.00 | 05/09/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175385181 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9,437.00 | 05/08/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430964 |
| Principal investigator 1 | ABBVIE INC. | $4,908.00 | 05/07/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202482791 |
| Principal investigator 1 | ABBVIE INC. | $3,782.60 | 05/07/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202482793 |
| Principal investigator 1 | ABBVIE INC. | $2,162.82 | 05/06/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202481459 |
| Principal investigator 1 | ABBVIE INC. | $5,546.00 | 05/06/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202481461 |
| Principal investigator 1 | Eli Lilly and Company | $4,820.00 | 04/28/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, 52 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN THE TREATMENT OF ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187877087 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,530.00 | 04/28/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384896 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,474.00 | 04/25/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384666 |
| Principal investigator 1 | ABBVIE INC. | $131.21 | 04/17/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202477651 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19.96 | 04/14/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385225 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $660.00 | 04/11/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277922 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $600.00 | 04/11/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277924 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,584.30 | 04/11/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278002 |
| Principal investigator 1 | Eli Lilly and Company | $6,976.16 | 04/10/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187878457 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,283.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175384936 |
| Principal investigator 1 | ABBVIE INC. | $1,794.60 | 04/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202473054 |
| Principal investigator 1 | ABBVIE INC. | $1,421.20 | 04/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202473057 |
| Principal investigator 1 | ABBVIE INC. | $1,365.28 | 04/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202473061 |
| Principal investigator 1 | Janssen Research & Development, LLC | $159.00 | 04/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384712 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28.74 | 04/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384992 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $212,421.98 | 04/01/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190306581 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,318.00 | 03/27/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175384765 |
| Principal investigator 1 | Janssen Research & Development, LLC | $30.86 | 03/24/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175385029 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,834.00 | 03/21/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175385145 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $270.00 | 03/12/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276327 |
| Principal investigator 1 | ABBVIE INC. | $1,244.40 | 03/07/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202460012 |
| Principal investigator 1 | ABBVIE INC. | $6,330.90 | 03/07/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | M24-727 - A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202460017 |
| Principal investigator 1 | ABBVIE INC. | $1,064.00 | 03/06/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202457186 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,760.00 | 03/06/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175384929 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,095.00 | 03/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175384776 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,573.00 | 03/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384856 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $28,932.80 | 02/26/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275607 |
| Principal investigator 1 | ABBVIE INC. | $3,321.00 | 02/18/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202452186 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,151.00 | 02/07/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384744 |
| Principal investigator 1 | ABBVIE INC. | $4,302.00 | 02/06/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202447127 |
| Principal investigator 1 | ABBVIE INC. | $5,991.90 | 02/05/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202444131 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,004.95 | 02/03/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274621 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,219.00 | 01/31/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175385164 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,989.00 | 01/27/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175384975 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,918.00 | 01/24/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175385151 |
| Principal investigator 1 | Eli Lilly and Company | $5,993.00 | 01/21/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187875573 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25.50 | 01/17/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175384674 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,801.60 | 01/13/2025 | Non-covered Recipient Entity Center For Clinical Studies Ltd Llp | A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1226084263 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,880.20 | 01/13/2025 | Non-covered Recipient Entity Center For Clinical Studies Ltd Llp | A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1226084266 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,905.30 | 01/13/2025 | Non-covered Recipient Entity Center For Clinical Studies Ltd Llp | A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1226084270 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $300.30 | 01/08/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273771 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,499.95 | 01/08/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223273773 |
| Principal investigator 1 | ABBVIE INC. | $1,421.20 | 01/02/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202433721 |
| Principal investigator 1 | ABBVIE INC. | $2,683.92 | 01/02/2025 | Non-covered Recipient Entity CENTER FOR CLINICAL STUDIES LTD LLP | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202433725 |